About Eyegenex
Eyegenex is a company based in San Diego (United States) founded in 2023. Eyegenex has raised $745 thousand across 1 funding round from investors including Newsight Tech Angels and NuFund. Eyegenex offers products and services including Glaucoma Treatment Drug, Diabetic Retinopathy Therapeutic, and NAION Treatment Drug. Eyegenex operates in a competitive market with competitors including Qlaris Bio, TearClear, 4B Technologies, Mannin Research and Aria Pharmaceuticals, among others.
- Headquarter San Diego, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$745 K (USD)
in 1 rounds
-
Latest Funding Round
$745 K (USD), Seed
Sep 07, 2023
-
Investors
Newsight Tech Angels
& 1 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Eyegenex
Eyegenex offers a comprehensive portfolio of products and services, including Glaucoma Treatment Drug, Diabetic Retinopathy Therapeutic, and NAION Treatment Drug.
Drug designed to reduce visual loss in Glaucoma patients through proven animal studies.
Therapeutic targeting blood vessel damage in Diabetic Retinopathy for vision preservation.
Drug for treating NAION to prevent progressive visual loss in affected individuals.
Funding Insights of Eyegenex
Eyegenex has successfully raised a total of $745K through 1 strategic funding round. The most recent funding activity was a Seed round of $745 thousand completed in September 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Eyegenex
Eyegenex has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Newsight Tech Angels and NuFund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment in biotechnology and healthcare startups is facilitated.
|
Locked | Locked | Locked | |
|
Technology sectors are invested in by NuFund venture capital firm.
|
Locked | Locked | Locked |
Investor details for Eyegenex
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eyegenex
Investment portfolio details for Eyegenex
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Eyegenex
Detailed financials for Eyegenex
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Eyegenex Comparisons
Peer comparison for Eyegenex
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Eyegenex
Eyegenex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Qlaris Bio, TearClear, 4B Technologies, Mannin Research and Aria Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-based technology is developed for treating ophthalmic diseases.
|
|
| Locked | Locked | Locked |
Filter technology for preservative-free ophthalmic drugs is developed.
|
|
| Locked | Locked | Locked |
Drugs for neurological disorders including ALS and Alzheimer's are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for vascular diseases are developed by Mannin Research.
|
|
| Locked | Locked | Locked |
Develops innovative drug technologies for multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for ophthalmic diseases including glaucoma are developed.
|
Detailed competitors of Eyegenex
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Eyegenex
Complete news archive for Eyegenex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eyegenex
Eyegenex was founded in 2023.
Eyegenex is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Eyegenex is a funded company, having raised a total of $745K across 1 funding round to date.
Eyegenex was founded in 2023 in San Diego, United States. Gene therapies targeting ophthalmic disorders are developed by the company within the biotechnology sector. Focus is placed on treatments for glaucoma to address vision loss and prevent blindness. Operations involve research and development of these therapies, with activities centered in the United States to support clinical advancements in eye care.
Eyegenex's top competitors include Qlaris Bio, 4B Technologies and Visiox Pharma.
Eyegenex offers Glaucoma Treatment Drug, Diabetic Retinopathy Therapeutic, and NAION Treatment Drug.
Eyegenex has 2 investors. Key investors include Newsight Tech Angels, and NuFund.